5 Result(s)
-
Article
Open AccessIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, ...
-
Article
Open AccessRUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell...
-
Article
Open AccessAdoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
-
Chapter
Allogeneic Transplantation for the Treatment of Multiple Myeloma
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells. The annual incidence is four per 100,000 individuals. It was estimated that 19,900 new cases would be dia...
-
Article
Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
Differentiation Syndrome, also known as all-trans retinoic acid (ATRA) syndrome, is a well-described clinical phenomenon occurring in patients with the M3 subtype of acute myeloid leukemia receiving ATRA chemo...
